Sinovac Biotech (FRA:SVQ) Additional Paid-In Capital : €496.3 Mil(As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sinovac Biotech Additional Paid-In Capital?

Sinovac Biotech's quarterly additional paid-in capital declined from Dec. 2022 (€510.3 Mil) to Jun. 2023 (€499.6 Mil) but then stayed the same from Jun. 2023 (€499.6 Mil) to Dec. 2023 (€496.3 Mil).

Sinovac Biotech's annual additional paid-in capital increased from Dec. 2021 (€484.7 Mil) to Dec. 2022 (€510.3 Mil) but then declined from Dec. 2022 (€510.3 Mil) to Dec. 2023 (€496.3 Mil).

Sinovac Biotech Additional Paid-In Capital Historical Data

The historical data trend for Sinovac Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Additional Paid-In Capital Chart

Sinovac Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

187.17

443.00

484.71

510.31

496.33

Sinovac Biotech Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															484.71	518.12	510.31	499.58	496.33

Sinovac Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sinovac Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinovac Biotech (FRA:SVQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (FRA:SVQ) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Sinovac Biotech (FRA:SVQ) Headlines

No Headlines